GlobeNewswire

Sky9 Capital Closes New Fund on $200 Million Hard Cap

Dela

HONG KONG, April 24, 2018 (GLOBE NEWSWIRE) -- Sky9 Capital announced today that it has completed the final closing of Sky9 Capital Fund III, L.P. with total capital commitments of $200 million.  With support from a strong group of world-class institutional investors, family foundations and entrepreneurs, the fund invests mainly in China-based businesses with a focus on early-stage companies in the internet, enterprise, and deep technology sectors.  Ron Cao, Founder & Managing Director, has over 18 years of extensive experience in venture capital and a track record of investing and growing successful China-based companies. 

The Sky9 team includes an experienced group of technologists, entrepreneurs and investors who have participated previously in the early-stage investments of some of the biggest technology companies in China including: DaVdian, eBroker, FaceU/Toutiao, FangDD, Innolight, Meituan/Dianping, ManBang Group, PPDai, PinDuoDuo, QingCloud, Rong360, Tujia, ZhaoYouWang and others.  With presence in Beijing, Shanghai, Shenzhen, and Silicon Valley, the firm has made a number of investments in the new fund including: ZhaoYouWang, the leading B2B e-commerce platform for the petroleum industry; eBroker, China's largest online marketplace for wealth management; Home, the leading social e-commerce platform for home furnishing; and Energy Monster, a power bank sharing platform.  Continuing its focus on early-stage and high-impact technology companies, Sky9 Capital invests between $1M to $10M in seed and Series A rounds, and $10M+ for expansion-stage companies.

"Sky9 has an exceptional team, and we have the experience and the commitment to continue to explore and invest in the biggest technology opportunities in China today," said Ron Cao. "The size and scale of the China internet and technology space continue to be unprecedented.  We are honored to have the chance to work with some extraordinary entrepreneurs in building exceptional companies together."

"Ron was a lead venture investor in the early-stage financing of our company," said Cliff Zhang, Co-founder & CEO of PPDai, a leading FinTech platform in China. "He has helped us tremendously over the years as we built out our business.  We look forward to our continued partnership with Sky9's new fund."  

"Sky9 Capital is eBroker's most important investor and partner," said Max He, Founder & CEO of eBroker, China's leading online wealth management platform. "In addition to providing advice and strategic planning, Sky9 focuses on building long-term value and is a true partner in growing together.  Congratulations to Ron and team for the successful fundraise."

For more information, please visit www.sky9capital.com.

About Sky9 Capital:

Sky9 Capital is a leading venture capital firm focused on investing in early-stage internet, enterprise and deep-tech start-ups in China. The firm invests with a systematic, analytical and conviction-based approach, focused on drawing deep market insights and discovering China's top talents. These principles guide our presence in Beijing, Shanghai, Shenzhen, and Silicon Valley as we support the innovators who will shape our future.  Through many years of cultivating deep relationships in the internet and technology sector and through its network of advisors, limited partners and strategic partners, the Sky9 team closely collaborates and shares resources with China's industry leaders like Baidu, Alibaba, Tencent, Toutiao, Meituan/Dianping, PinDuoDuo, Ctrip, PPDai, Rong360, Xiaomi and more.  For more information, please visit www.sky9capital.com.

Contact:

Cindy Chen
T: (86) 21 5238 3699
E: cindy@sky9capital.com

A photo accompanying this announcement is available at http://resource.globenewswire.com/Resource/Download/8118babc-12f8-4e57-8275-56eba9528a2d




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Sky9 Capital via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Immunicum AB (publ) Announces Upcoming Investor Events in January22.1.2019 08:30Pressmeddelande

Press Release 22 January 2019 Immunicum AB (publ) Announces Upcoming Investor Events in January Immunicum AB (publ; IMMU.ST) announced today that Carlos de Sousa, CEO of Immunicum, and other members of the management team will present at upcoming investor conferences in January. Biomed Investor Event by Invest Securities Date: January 22, 2019 Venue: Les Salons Hoche, 9 Avenue Hoche, Paris, France Redeye Fight Cancer Seminar Date: January 22, 2019 Presentation Time: 11.15 am CET Panel: 11.25 am CET Venue: Master Samuelsgatan 42, Stockholm, Sweden Aktiespararna - Stora Aktiedagen Date: January 29, 2019 Presentation Time: 8.30 - 9.00 am CET Panel: "Samtal om cancerbekämpning", 10:50 am CET Venue: Medicon Village, Scheelevägen 2, Lund, Sweden For more information, please contact: Carlos de Sousa, CEO, Immunicum Telephone: +46 (0) 31 41 50 52 E-mail: info@immunicum.com Michaela Gertz, CFO, Immunicum Telephone: +46 70 926 17 75 E-mail: ir@immunicum.com Media Relations Gretchen Schweitzer an

Immunicum AB (publ) meddelar idag kommande presentationstillfällen under januari22.1.2019 08:30Pressmeddelande

Pressmeddelande 22 januari 2019 Immunicum AB (publ) meddelar idag kommande presentationstillfällen under januari Immunicum AB (publ; IMMU.ST) meddelar idag att Immunicums VD, Carlos de Sousa och andra medlemmar av ledningsgruppen kommer presentera vid följande investerarevent under januari. Biomed Investor Event by Invest Securities Datum: 22 januari 2019 Plats: Les Salons Hoche, 9 Avenue Hoche, Paris, France RedEye Fight Cancer Seminar Datum: 22 januari 2019 Presentationstid: 11.15 am CET Panel: 11.25 am CET Plats: Master Samuelsgatan 42, Stockholm, Sweden Aktiespararna - Stora Aktiedagen Datum: 29 januari 2019 Presentationstid: 8.30 - 9.00 am CET Panel: "Samtal om cancerbekämpning", 10:50 am CET Plats: Medicon Village, Scheelevägen 2, Lund, Sweden För ytterligare information kontakta: Carlos de Sousa, VD, Immunicum Telefon: +46 (0) 31 41 50 52 E-post: info@immunicum.com Michaela Gertz, Finanschef, Immunicum Telefon: +46 (0) 70 926 17 75 E-post: ir@immunicum.com Media Relations Gretch

Immunicum AB (publ) meddelar att resultaten från den kliniska fas I/II-studien med ilixadencel vid långt framskriden levercancer publicerats i Frontiers in Oncology21.1.2019 08:30Pressmeddelande

Pressmeddelande 21 januari 2019 Immunicum AB (publ) meddelar att resultaten från den kliniska fas I/II-studien med ilixadencel vid långt framskriden levercancer publicerats i Frontiers in Oncology Immunicum AB (publ; IMMU.ST) meddelar idag att den slutliga analysen av data från den undersökande kliniska studien med ilixadencel hos patienter med långt framskriden levercancer har publicerats i tidskriften, Frontiers in Oncology . Dessa data bekräftar de tidigare meddelade positiva egenskaperna gällande säkerhet och tolerabilitet för ilixadencel, både när det ges som enda behandling och i kombination med första linjens standardbehandling, sorafenib. Dessutom påvisades ökade nivåer av tumörspecifika CD8+ T-celler i cirkulerande blod för en majoritet av de utvärderbara patienterna, vilket indikerar ett systemiskt immunologiskt svar. De fullständiga resultaten ger ytterligare insikter om ilixadencels verkningsmekanism, tecken på klinisk effekt samt viktig information som kommer att vara vägl

Immunicum AB (publ) Announces Publication of Phase I/II Clinical Trial Results of Ilixadencel in Advanced Hepatocellular Carcinoma in Frontiers in Oncology21.1.2019 08:30Pressmeddelande

Press Release 21 January 2019 Immunicum AB (publ) Announces Publication of Phase I/II Clinical Trial Results of Ilixadencel in Advanced Hepatocellular Carcinoma in Frontiers in Oncology Immunicum AB (publ; IMMU.ST) announced today that the final data analysis from the exploratory clinical study of ilixadencel in patients with advanced hepatocellular carcinoma (HCC) has been published in the journal, Frontiers in Oncology . The data confirms previously communicated positive safety and tolerability of ilixadencel when administered both alone and in combination with current first-line standard of care, sorafenib. In addition, the data demonstrate an increased frequency of tumor-specific CD8+ T cells in circulating blood for a majority of evaluable patients, indicating a systemic immune response. The complete results provide further insight on ilixadencel's mode of action, signs of clinical activity and important information that will guide the next stage of clinical development. As commun

Karolinska Development's portfolio company Modus Therapeutics completes enrollment in Phase II study with sevuparin7.1.2019 12:00Pressmeddelande

STOCKHOLM, January 7, 2019. Karolinska Development's portfolio company Modus Therapeutics announces that the patient enrollment has been completed in the Phase II study with sevuparin in patients with sickle cell disease (SCD). The results from the study is expected in mid 2019. Modus Therapeutic's randomized, double blind study contains 140 SCD-patients with Acute Vaso Occlusive Crisis (VOC). It compares intravenously administered sevuparin with placebo. The primary endpoint of the study is the demonstration of a reduced time to resolution of patient's VOC. Clincal sites across Europe and the Middle East took part in the study that was conducted in conjunction with Modus Therapeutics' co development partner Ergomed. SCD has a high unmet medical need as there are currently no approved therapies for VOCs. It is an inherited blood disorder that affects between 90,000 to 100,000 patients in the U.S. and is characterized by severely painful VOCs that lead to organ damage due to a lack of o

Karolinska Development's portfolio company Modus Therapeutics completes enrollment in Phase II study with sevuparin7.1.2019 12:00Pressmeddelande

STOCKHOLM, January 7, 2019. Karolinska Development's portfolio company Modus Therapeutics announces that the patient enrollment has been completed in the Phase II study with sevuparin in patients with sickle cell disease (SCD). The results from the study is expected in mid 2019. Modus Therapeutic's randomized, double blind study contains 140 SCD-patients with Acute Vaso Occlusive Crisis (VOC). It compares intravenously administered sevuparin with placebo. The primary endpoint of the study is the demonstration of a reduced time to resolution of patient's VOC. Clincal sites across Europe and the Middle East took part in the study that was conducted in conjunction with Modus Therapeutics' co development partner Ergomed. SCD has a high unmet medical need as there are currently no approved therapies for VOCs. It is an inherited blood disorder that affects between 90,000 to 100,000 patients in the U.S. and is characterized by severely painful VOCs that lead to organ damage due to a lack of o

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum